Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients
Phase 3
- Conditions
- Migraine
- Registration Number
- LBCTR2019060240
- Lead Sponsor
- ovartis Pharma Services Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 49
Inclusion Criteria
1.Documented history of migraine in the 12 months prior to screening
2.4-14 days per month of migraine symptoms
3.>=80% diary compliance during the Baseline period
Exclusion Criteria
1.>50 years old at migraine onset
2.Pregnant or nursing
3.History of cluster or hemiplegic headache
4.Evidence of seizure or major psychiatric disorder
5.Score of 19 or higher on the BDI
6.Active chronic pain syndrome
7.Cardiac or hepatic disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method